Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment |
Han, Sung Joon
(Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine)
Han, Woosik (Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine) Song, Hee-Jung (Department of Neurology, Chungnam National University School of Medicine) Kim, Cuk-Seong (Department of Physiology, Chungnam National University School of Medicine) Jeong, Seong-Mok (Department of Veterinary Medicine, Chungnam National University School of Medicine) Kang, Min Woong (Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine) |
1 | Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008;17 Suppl 4:S41-7. |
2 | Sell LL, Cullen ML, Whittlesey GC, et al. Hemorrhagic complications during extracorporeal membrane oxygenation: prevention and treatment. J Pediatr Surg 1986;21:1087-91. DOI |
3 | Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs 2013;36:208-16. DOI |
4 | Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993;88(5 Pt 2):II432-6. |
5 | Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens: I. the responding cell. J Exp Med 1972;136:128-42. |
6 | Gery I, Handschumacher RE. Potentiation of the T lymphocyte response to mitogens: III. properties of the mediator( s) from adherent cells. Cell Immunol 1974;11:162-9. DOI |
7 | Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens: II. the cellular source of potentiating mediator(s). J Exp Med 1972;136:143-55. DOI |
8 | Bronicki RA, Hall M. Cardiopulmonary bypass-induced inflammatory response: pathophysiology and treatment. Pediatr Crit Care Med 2016;17(8 Suppl 1):S272-8. DOI |
9 |
Muto S, Imai M, Asano Y. Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on |
10 | Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol 1995;26: 1627-32. |
11 | Zangrillo A, Landoni G, Biondi-Zoccai G, et al. A metaanalysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 2013;15:172-8. |
12 | Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009;22:141-5. DOI |
13 | Han SJ, Kim HS, Kim KI, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci 2011;26:945-50. DOI |
14 | Traverso CI, Caprini JA, Arcelus JI. The normal thromboelastogram and its interpretation. Semin Thromb Hemost 1995;21 Suppl 4:7-13. |
![]() |